Seth Baum
Cardiovascular Disease · Boca Raton, FLNPI 1649210121
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Amgen at 25.8% of the total. Reporting peaked in 2020 at $149,487 and has fallen 56.5% since, to $64,979 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 375 payments — averaging $1377.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$133K
- Boehringer Ingelheim$69K
- Eli Lilly$64K
- Ionis Pharmaceuticals, Inc.$56K
- Kaneka Medical America LLC$45K
- Novartis$36K
- plus $114K from 11 others
Across 1,390 payments — averaging $7661.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4.4M
- Amgen$1.2M
- Novartis$1.1M
- Regeneron$883K
- AstraZeneca$729K
- Novo Nordisk AS$577K
- plus $1.7M from 17 others
What the payments were for
- Consulting fees$223,34643%
- Speaking & faculty fees$253,99749%
- Travel & lodging$32,8276%
- Food & beverage$6,3651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 104 | $133,016 |
| Boehringer Ingelheim | 38 | $68,699 |
| Eli Lilly | 82 | $63,524 |
| Ionis Pharmaceuticals, Inc. | 26 | $55,752 |
| Kaneka Medical America LLC | 3 | $44,754 |
| Novartis | 21 | $36,410 |
| Regeneron Healthcare Solutions, Inc. | 23 | $31,730 |
| Lilly USA, LLC | 29 | $20,380 |
| Regeneron | 16 | $15,899 |
| Esperion Therapeutics, Inc. | 5 | $11,387 |
| Novo Nordisk | 7 | $11,180 |
| E.r. Squibb & Sons, L.L.C. | 10 | $9,340 |
| AbbVie | 1 | $6,338 |
| AstraZeneca(2 entities) | 2 | $4,914 |
| Merck | 6 | $3,037 |
| Boston Scientific | 1 | $133 |
| Echosens North America, Inc. | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$129,103
- JARDIANCE$89,849
- EVKEEZA$46,551
- LIPOSORBER$42,254
- TRYNGOLZA$34,152
- OLEZARSEN$18,243
- LEQVIO$15,931
- NEXLIZET$11,387
- NEXLETOL$11,387
- Ozempic$10,875
- PELACARSEN$8,910
- UBRELVY$6,338
- LUX-Dx Insertable Cardiac Monitor$133
How this compares
$516,534 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 18 | $14,784 |
| Ezetimibe | 16 | $214 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boca Raton
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
- David WolinskyWeston$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.